In preclinical studies, engineered GPC3-CAR-T cells could effectively eliminate GPC3-positive HCC cells in HCC xenograft mouse models, demonstrating their clinical potential for treatment [157–159]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.